T-cell receptor recognizing HIV-1 Pol-derived peptide–MHC complex (TCR-HIV-Pol-pMHC)

T-cell receptors (TCRs) recognizing HIV-1 Pol-derived peptide–MHC complexes are specialized proteins on the surface of T lymphocytes that identify viral antigens presented by infected cells. The HIV-1 Pol polyprotein is a critical target because it contains highly conserved enzymes such as reverse transcriptase, integrase, and protease, which are essential for the viral life cycle [2]. These TCRs bind specifically to Pol-derived peptides, such as the HLA-A*02:01-restricted ILKEPVHGV epitope, when they are displayed by Major Histocompatibility Complex (MHC) molecules [1][4]. This binding event triggers the activation of cytotoxic T lymphocytes (CTLs), leading to the secretion of perforin and granzymes that induce apoptosis in the HIV-infected cell [3]. In the context of modern medicine, these TCRs are being utilized in adoptive cell therapies, where patients' T cells are engineered to express high-affinity Pol-specific TCRs to enhance the immune system's ability to control or eliminate the latent HIV reservoir [1]. However, challenges remain, including the potential for viral escape through mutations in the Pol sequence and the risk of off-target immune responses against host tissues [4].

Other names

HIV-1 Pol-specific T-cell receptorPol-specific TCRTCR targeting HIV-1 Pol epitopeHLA-A*02:01-restricted HIV-1 Pol TCR

Recognition of HIV-1 Pol-derived peptides presented by MHC molecules on the surface of infected cells, leading to T-cell activation and targeted lysis of the host cell.